WASHINGTON, DC--(Marketwire - April 04, 2008) - Kinexum Metabolics, Inc. (KMI) announced two abstracts will be presented on INGAP Peptide at the Keystone Symposia on Islet and Beta Cell Biology to be held April 6-10, 2008. These two studies demonstrate important new data to advance the development of INGAP Peptide as a treatment to regenerate fully functioning islet cells that can restore insulin secretion for Type 1 diabetes patients. “We are encouraged by these new studies and believe they demonstrate great potential for INGAP Peptide as a therapeutic approach for Type 1 diabetes and insulin-dependent Type 2 diabetes,” stated Dr. Alexander Fleming, founder and Chief Medical Officer of KMI and a well-known authority on metabolic drug development. “These new data demonstrate for the first time induction of endocrine cells from a human pancreatic ductal cell line in vitro and the use of combination therapy to induce islet regeneration and clinical remission in a model of established (not new onset) T1 diabetes.”
